Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension - Chin, Kelly M.; Sitbon, Olivier; Doelberg, Martin; Feldman, Jeremy; Gibbs, J. Simon R.; Grünig, Ekkehard; Hoeper, Marius M.; Martin, Nicolas; Mathai, Stephen C.; McLaughlin, Vallerie V.; Perchenet, Loïc; Poch, David; et al. (Journal of the American College of Cardiology, 2021)
Keywords: Acetamides - therapeutic use; Adult; Aged; Antihypertensive Agents - therapeutic use; Cardiovascular; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists - therapeutic use; Female; Humans; Life Sciences; macitentan; Male; Middle Aged; Phosphodiesterase 5 Inhibitors - therapeutic use; pulmonary arterial hypertension; Pulmonary Arterial Hypertension - drug therapy; Pyrazines - therapeutic use; Pyrimidines - therapeutic use; randomized controlled trial; selexipag; Sulfonamides - therapeutic use; Tadalafil - therapeutic use; triple combination therapy; selexipag; PDE5i; triple combination therapy; AE; CI; PVR; randomized controlled trial; NT-proBNP; macitentan; ERA; PAH; pulmonary arterial hypertension; 6MWD; FC; functional class; adverse event; 6-minute walk distance; phosphodiesterase type-5 inhibitor; N-terminal pro–brain natriuretic peptide; endothelin receptor antagonist; confidence interval; pulmonary vascular resistance